{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:08Z","timestamp":1793382908016,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01641-5","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:54:21Z","timestamp":1779807261000},"page":"811-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2000-6763","authenticated-orcid":false,"given":"S. L.","family":"van der Zeeuw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-9797","authenticated-orcid":false,"given":"S. J.","family":"van Tilburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"B. C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-3643","authenticated-orcid":false,"given":"B. C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-4435","authenticated-orcid":false,"given":"V. A. S. H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-252X","authenticated-orcid":false,"given":"M. B. S.","family":"Crombag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-0358","authenticated-orcid":false,"given":"T.","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"1641_CR1","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SmPC) of Privigen. 2008 [cited 2025 10-02]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/privigen-epar-product-information_en.pdf."},{"key":"1641_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/ITT.S31136","volume":"2","author":"S Jolles","year":"2013","unstructured":"Jolles S. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. Immunotargets Ther. 2013;2:125\u201333.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"1641_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom6010015","volume":"6","author":"AF Barahona Afonso","year":"2016","unstructured":"Barahona Afonso AF, Jo\u00e3o CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules. 2016;6(1):15.","journal-title":"Biomolecules"},{"issue":"3, Supplement","key":"1641_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3, Supplement):S1\u201346.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1641_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41576-023-00656-z","volume":"25","author":"YT Akalu","year":"2024","unstructured":"Akalu YT, Bogunovic D. Inborn errors of immunity: an expanding universe of disease and genetic architecture. Nat Rev Genet. 2024;25(3):184\u201395.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"1641_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2023.12.002","volume":"8","author":"JA Allen","year":"2024","unstructured":"Allen JA, Clarke AE, Harbo T. A practical guide to identify patients with multifocal motor neuropathy, a treatable immune-mediated neuropathy. Mayo Clinic Proc Innov Qual Outcomes. 2024;8(1):74\u201381.","journal-title":"Mayo Clinic Proc Innov Qual Outcomes."},{"issue":"3-4","key":"1641_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3\u20134):161\u201372.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"1641_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150\u201363.","journal-title":"Neuroepidemiology"},{"issue":"21","key":"1641_CR9","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","volume":"129","author":"MP Lambert","year":"2017","unstructured":"Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829\u201335.","journal-title":"Blood"},{"issue":"3","key":"1641_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1641_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747\u201355.","journal-title":"N Engl J Med"},{"issue":"11-12","key":"1641_CR12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14737175.2022.2169134","volume":"22","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC, Latov N, Kuitwaard K. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations. Expert Rev Neurother. 2022;22(11\u201312):953\u201362.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"1641_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0161-5890(97)00091-6","volume":"34","author":"TE Mollnes","year":"1997","unstructured":"Mollnes TE, Andreassen IH, H\u00f8g\u00e5sen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol. 1997;34(10):719\u201329.","journal-title":"Mol Immunol"},{"issue":"4","key":"1641_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/jns5.12048","volume":"18","author":"M Berger","year":"2013","unstructured":"Berger M, McCallus DE, Lin CS. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst. 2013;18(4):275\u201396.","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"1641_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"B Buchwald","year":"2002","unstructured":"Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome. Ann Neurol. 2002;51(6):673\u201380.","journal-title":"Ann Neurol"},{"issue":"6","key":"1641_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/jps.10364","volume":"92","author":"RJ Hansen","year":"2003","unstructured":"Hansen RJ, Balthasar JP. Pharmacokinetic\/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003;92(6):1206\u201315.","journal-title":"J Pharm Sci"},{"key":"1641_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1641_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80\u20139.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1641_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","volume":"29","author":"MR Stein","year":"2009","unstructured":"Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, et al. Safety and efficacy of Privigen\u00ae, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137\u201344.","journal-title":"J Clin Immunol"},{"issue":"s1","key":"1641_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1529-8027.2011.00304.x","volume":"16","author":"PA van Doorn","year":"2011","unstructured":"van Doorn PA, Kuitwaard K, Jacobs BC. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst. 2011;16(s1):38\u201340.","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"1641_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.iac.2008.07.003","volume":"28","author":"CM Roifman","year":"2008","unstructured":"Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin N Am. 2008;28(4):875\u20136.","journal-title":"Immunol Allergy Clin N Am."},{"key":"1641_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.638816","volume":"12","author":"SR Beydoun","year":"2021","unstructured":"Beydoun SR, Sharma KR, Bassam BA, Pulley MT, Shije JZ, Kafal A. Individualizing therapy in CIDP: a mini-review comparing the pharmacokinetics of Ig with SCIg and IVIg. Front Neurol. 2021;12:638816.","journal-title":"Front Neurol"},{"issue":"8","key":"1641_CR23","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/acn3.52098","volume":"11","author":"Z Li","year":"2024","unstructured":"Li Z, Roepcke S, Franke R, Yel L. Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Ann Clin Transl Neurol. 2024;11(8):1977\u201387.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1641_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WCJ, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome. Ann Neurol. 2009;66(5):597\u2013603.","journal-title":"Ann Neurol"},{"issue":"10","key":"1641_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","volume":"85","author":"L Vlam","year":"2014","unstructured":"Vlam L, Cats EA, Willemse E, Franssen H, Medic J, Piepers S, et al. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85(10):1145\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1641_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/cpt.693","volume":"102","author":"WJR Fokkink","year":"2017","unstructured":"Fokkink WJR, Koch BCP, Ramakers CRB, van Doorn PA, van Gelder T, Jacobs BC. Pharmacokinetics and pharmacodynamics of intravenous Immunoglobulin G maintenance therapy in chronic immune-mediated neuropathies. Clin Pharmacol Ther. 2017;102(4):709\u201316.","journal-title":"Clin Pharmacol Ther"},{"key":"1641_CR27","doi-asserted-by":"crossref","unstructured":"Fokkink WJR, van Tilburg SJ, de Winter BCM, Sassen SDT, van Doorn PA, Koch BCP, Jacobs BC. Population pharmacokinetic modelling of intravenous immunoglobulin treatment in patients with Guillain-Barre Syndrome. Clin Pharmacokinet. 2022;61(9):1285-96.","DOI":"10.1007\/s40262-022-01136-z"},{"issue":"9","key":"1641_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometr Syst Pharmacol. 2012;1(9):e6.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"1641_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/psp.2013.71","volume":"3","author":"RN Upton","year":"2014","unstructured":"Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3\u2014introduction to pharmacodynamic modeling methods. CPT Pharmacomet Syst Pharmacol. 2014;3(1):88.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1641_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"7","key":"1641_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"4 Pt 2","key":"1641_CR32","first-page":"F632","volume":"247","author":"P Boer","year":"1984","unstructured":"Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247(4 Pt 2):F632\u20136.","journal-title":"Am J Physiol"},{"issue":"9","key":"1641_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i09","volume":"33","author":"K Soetaert","year":"2010","unstructured":"Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9):1\u201325.","journal-title":"J Stat Softw"},{"key":"1641_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern Applied Statistics with S","author":"WN Venables","year":"2002","unstructured":"Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York: Springer; 2002.","edition":"4"},{"key":"1641_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106192","volume":"80","author":"MA Tegenge","year":"2020","unstructured":"Tegenge MA, Mahmood I. Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. Int Immunopharmacol. 2020;80:106192.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1641_CR36","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1111\/bcp.14712","volume":"87","author":"JL Lee","year":"2021","unstructured":"Lee JL, Mohd Saffian S, Makmor-Bakry M, Islahudin F, Alias H, Noh LM, et al. Population pharmacokinetic modelling of intravenous immunoglobulin in patients with predominantly antibody deficiencies. Br J Clin Pharmacol. 2021;87(7):2956\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"1641_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108472","volume":"104","author":"G Navarro-Mora","year":"2022","unstructured":"Navarro-Mora G, Alberti JJ, Mondou E, Vilardell D, Vicente Torres J, Ayguasanosa J, et al. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases. Int Immunopharmacol. 2022;104:108472.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1641_CR38","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.clinthera.2024.09.018","volume":"46","author":"JL Lee","year":"2024","unstructured":"Lee JL, Mohamed Shah N, Makmor-Bakry M, Islahudin F, Alias H, Mohd SS. Population pharmacokinetic model of intravenous immunoglobulin in patients treated for various immune system disorders. Clin Ther. 2024;46(12):e25\u201337.","journal-title":"Clin Ther"},{"key":"1641_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1478419","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Roepcke S, Franke R, Yel L. Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy. Front Neurol. 2024;15:1478419.","journal-title":"Front Neurol"},{"issue":"6","key":"1641_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3810\/pgm.2013.11.2712","volume":"125","author":"CB Landersdorfer","year":"2013","unstructured":"Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, et al. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med. 2013;125(6):53\u201361.","journal-title":"Postgrad Med"},{"issue":"1","key":"1641_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.clinthera.2019.11.013","volume":"42","author":"D Luo","year":"2020","unstructured":"Luo D, Baheti G, Tortorici MA, Hofmann J, Rojavin MA. Pharmacometric analysis of IgPro10 in Japanese and non-Japanese patients with primary immunodeficiency. Clin Ther. 2020;42(1):196-209.e195.","journal-title":"Clin Ther"},{"issue":"Pt A","key":"1641_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109331","volume":"113","author":"Z Li","year":"2022","unstructured":"Li Z, Follman K, Freshwater E, Engler F, Yel L. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies. Int Immunopharmacol. 2022;113(Pt A):109331.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"1641_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/psp4.12647","volume":"10","author":"MA Tortorici","year":"2021","unstructured":"Tortorici MA, Yuraszeck T, Cornblath D, Bril V, Hartung HP, Sobue G, et al. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT Pharmacometr Syst Pharmacol. 2021;10(8):839\u201350.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1641_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106005","volume":"81","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Baheti G, Chapdelaine H, Hofmann J, Rojavin M, Tortorici M, et al. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra R) dosing in patients with primary immunodeficiency. Int Immunopharmacol. 2020;81:106005.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1641_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13223-024-00938-z","volume":"20","author":"VHD Kim","year":"2025","unstructured":"Kim VHD, Upton JEM, Derfalvi B, Hildebrand KJ, McCusker C. Inborn errors of immunity (primary immunodeficiencies). Allergy Asthma Clin Immunol. 2025;20(3):76.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1641_CR46","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2019.02593","volume":"10","author":"ESJ Edwards","year":"2019","unstructured":"Edwards ESJ, Bosco JJ, Aui PM, Stirling RG, Cameron PU, Chatelier J, et al. Predominantly antibody-deficient patients with non-infectious complications have reduced naive B, Treg, Th17, and Tfh17 cells. Front Immunol. 2019;10:2593.","journal-title":"Front Immunol"},{"key":"1641_CR47","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SmPC) of Hizentra. 2011 [cited 2026 03-02]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hizentra-epar-product-information_en.pdf."},{"issue":"7","key":"1641_CR48","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/jimmunol\/188.7.2948","volume":"188","author":"D Vetrie","year":"2012","unstructured":"Vetrie D, Vo\u0159echovsk\u00fd I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. J Immunol. 2012;188(7):2948\u201355.","journal-title":"J Immunol"},{"issue":"5","key":"1641_CR49","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e78.","journal-title":"J Allergy Clin Immunol"},{"key":"1641_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928062","volume":"13","author":"M Ballow","year":"2022","unstructured":"Ballow M, S\u00e1nchez-Ram\u00f3n S, Walter JE. Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases. Front Immunol. 2022;13:928062.","journal-title":"Front Immunol"},{"issue":"5","key":"1641_CR51","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149(5):1525\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"1641_CR52","doi-asserted-by":"publisher","first-page":"5340241","DOI":"10.1155\/ah\/5340241","volume":"2025","author":"C Siffel","year":"2025","unstructured":"Siffel C, Davids MS, Anderson-Smits C, Kamieniak M, Ren K, Ardeshir-Rouhani-Fard S, et al. Multiple myeloma and secondary immunodeficiency: a retrospective database analysis assessing burden of infection and treatment patterns. Adv Hematol. 2025;2025:5340241.","journal-title":"Adv Hematol"},{"key":"1641_CR53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.intimp.2019.03.034","volume":"71","author":"T Dumas","year":"2019","unstructured":"Dumas T, Berry NS, Wolfsegger M, Jolles S, McCoy B, Yel L. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. Int Immunopharmacol. 2019;71:404\u201310.","journal-title":"Int Immunopharmacol"},{"key":"1641_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.intimp.2018.11.008","volume":"66","author":"MA Tortorici","year":"2019","unstructured":"Tortorici MA, Lawo JP, Weide R, Jochems J, Puli S, Hofmann J, et al. Privigen R has similar pharmacokinetic properties in primary and secondary immune deficiency. Int Immunopharmacol. 2019;66:119\u201326.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1641_CR55","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","volume":"8","author":"LB Avery","year":"2016","unstructured":"Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064\u201378.","journal-title":"MAbs"},{"issue":"6","key":"1641_CR56","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","volume":"31","author":"M Borte","year":"2011","unstructured":"Borte M, Quinti I, Soresina A, Fern\u00e1ndez-Cruz E, Ritchie B, Schmidt DS, et al. Efficacy and safety of subcutaneous vivaglobin\u00ae replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011;31(6):952\u201361.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1641_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometr Syst Pharmacol. 2013;2(4):e38.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"1641_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103710","volume":"24","author":"MG Danieli","year":"2025","unstructured":"Danieli MG, Antonelli E, Gammeri L, Longhi E, Cozzi MF, Palmeri D, et al. Intravenous immunoglobulin as a therapy for autoimmune conditions. Autoimmunity Rev. 2025;24(1):103710.","journal-title":"Autoimmunity Rev"},{"issue":"2","key":"1641_CR59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mus.24207","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner A, Barnett C, Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve. 2014;50(2):164\u20139.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1641_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40120-020-00190-8","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy. Neurol Ther. 2020;9(2):213\u201327.","journal-title":"Neurol Ther"},{"issue":"8","key":"1641_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16365","volume":"31","author":"R Bellanti","year":"2024","unstructured":"Bellanti R, Rinaldi S. Guillain-Barr\u00e9 syndrome: a comprehensive review. Eur J Neurol. 2024;31(8):e16365.","journal-title":"Eur J Neurol"},{"issue":"8","key":"1641_CR62","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","volume":"25","author":"PC Gandiga","year":"2023","unstructured":"Gandiga PC, Ghetie D, Anderson E, Aggrawal R. Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use. Curr Rheumatol Rep. 2023;25(8):152\u201368.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"1641_CR63","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10875-013-9876-3","volume":"33","author":"M Berger","year":"2013","unstructured":"Berger M, Jolles S, Orange JS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33(5):984\u201390.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1641_CR64","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-7.e11.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1641_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/cei.12955","volume":"188","author":"JP Hodkinson","year":"2017","unstructured":"Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol. 2017;188(3):353\u201362.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1641_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1542\/peds.2004-1773","volume":"117","author":"N Aladangady","year":"2006","unstructured":"Aladangady N, McHugh S, Aitchison TC, Wardrop CA, Holland BM. Infants\u2019 blood volume in a controlled trial of placental transfusion at preterm delivery. Pediatrics. 2006;117(1):93\u20138.","journal-title":"Pediatrics"},{"issue":"12","key":"1641_CR67","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/j.1552-4604.1991.tb03688.x","volume":"31","author":"KH Rand","year":"1991","unstructured":"Rand KH, Gibbs K, Derendorf H, Graham-Pole J. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol. 1991;31(12):1151\u20134.","journal-title":"J Clin Pharmacol"},{"key":"1641_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00626","volume":"5","author":"N Compagno","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.","journal-title":"Front Immunol"},{"issue":"1","key":"1641_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","volume":"119","author":"UJ Sachs","year":"2006","unstructured":"Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology. 2006;119(1):83\u20139.","journal-title":"Immunology"},{"issue":"7","key":"1641_CR70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/acn3.307","volume":"3","author":"WJ Fokkink","year":"2016","unstructured":"Fokkink WJ, Haarman AE, Tio-Gillen AP, van Rijs W, Huizinga R, van Doorn PA, et al. Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. Ann Clin Transl Neurol. 2016;3(7):547\u201351.","journal-title":"Ann Clin Transl Neurol"},{"key":"1641_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420986747","volume":"14","author":"S Su","year":"2021","unstructured":"Su S, Liu Q, Zhang X, Wen X, Lei L, Shen F, et al. VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis. Ther Adv Neurol Disord. 2021;14:1756286420986747.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1641_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cei.12002","volume":"171","author":"V Gouilleux-Gruart","year":"2013","unstructured":"Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186\u201394.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"1641_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.clim.2010.05.006","volume":"136","author":"T Freiberger","year":"2010","unstructured":"Freiberger T, Grodeck\u00e1 L, Rav\u010dukov\u00e1 B, Ku\u0159ecov\u00e1 B, Postr\u00e1neck\u00e1 V, Vl\u010dek J, et al. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol. 2010;136(3):419\u201325.","journal-title":"Clin Immunol"},{"issue":"10","key":"1641_CR74","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/ajg.2016.306","volume":"111","author":"T Billiet","year":"2016","unstructured":"Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, et al. A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease. Am J Gastroenterol. 2016;111(10):1438\u201345.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1641_CR75","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1641_CR76","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW van Valkengoed","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ. All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology. Clin Pharmacokinet. 2025;64(2):173\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"Supplement_4","key":"1641_CR77","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/ajhp\/zxz233","volume":"76","author":"BS Figgins","year":"2019","unstructured":"Figgins BS, Aitken SL, Whited LK. Optimization of intravenous immune globulin use at a comprehensive cancer center. Am J Health Syst Pharm. 2019;76(Supplement_4):S102\u20136.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1641_CR78","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/CND.0000000000000359","volume":"23","author":"TP Nguyen","year":"2021","unstructured":"Nguyen TP, Nguyen TD, Zhu L, Ayish D, Karnik K, Bokhari H, et al. Precision intravenous immunoglobulin dosing and clinical outcomes: a retrospective chart review. J Clin Neuromuscul Dis. 2021;23(1):18\u201323.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"3","key":"1641_CR79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1060028019880300","volume":"54","author":"JW Grindeland","year":"2020","unstructured":"Grindeland JW, Grindeland CJ, Moen C, Leedahl ND, Leedahl DD. Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study. Ann Pharmacother. 2020;54(3):205\u201312.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1641_CR80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13223-023-00841-z","volume":"19","author":"M Harmon","year":"2023","unstructured":"Harmon M, Riazi K, Callum J, Arnold DM, Barty R, Sidhu D, et al. Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature. Allergy Asthma Clin Immunol. 2023;19(1):85.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"128","key":"1641_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111447","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Follman K, Freshwater E, Engler F, Yel L. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. Int Immunopharmacol. 2024;15(128):111447.","journal-title":"Int Immunopharmacol"},{"key":"1641_CR82","doi-asserted-by":"crossref","unstructured":"Jolles SR, Ponsford MJ, Lawo J-P, Rojavin M. Impact of endogenous IgG levels on immunoglobulin replacement efficiency in primary immunodeficiency (PID). J Allergy Clin Immunol. 2016;137(2, Supplement):AB201.","DOI":"10.1016\/j.jaci.2015.12.787"},{"issue":"3","key":"1641_CR83","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","volume":"37","author":"RL Wasserman","year":"2009","unstructured":"Wasserman RL, Church JA, Peter HH, Sleasman JW, Melamed I, Stein MR, et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci. 2009;37(3):272\u20138.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1641_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2512217","volume":"17","author":"SPH van den Berg","year":"2025","unstructured":"van den Berg SPH, Adolfsen PEA, Dorlo TPC, Rispens T. Does one model fit all mAbs? An evaluation of population pharmacokinetic models. MAbs. 2025;17(1):2512217.","journal-title":"MAbs"},{"issue":"4","key":"1641_CR85","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1208\/s12248-016-9911-4","volume":"18","author":"CM Ng","year":"2016","unstructured":"Ng CM, Fielder PJ, Jin J, Deng R. Mechanism-based competitive binding model to investigate the effect of neonatal Fc receptor binding affinity on the pharmacokinetic of humanized anti-VEGF monoclonal IgG1 antibody in Cynomolgus Monkey. AAPS J. 2016;18(4):948\u201359.","journal-title":"AAPS J"},{"issue":"11","key":"1641_CR86","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40262-025-01549-6","volume":"64","author":"D Ternant","year":"2025","unstructured":"Ternant D, Le Tilly O, Cartron G, Desvignes C, Bensalem A, Mulleman D, et al. Immunoglobulin G receptors (Fc\u03b3R), in addition to target-antigen and neonatal Fc receptor (FcRn), influence rituximab pharmacokinetics. Clin Pharmacokinet. 2025;64(11):1639\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1641_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10928-017-9559-4","volume":"45","author":"C Niederalt","year":"2018","unstructured":"Niederalt C, Kuepfer L, Solodenko J, Eissing T, Siegmund HU, Block M, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018;45(2):235\u201357.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1641_CR88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10928-010-9181-1","volume":"38","author":"DK Shah","year":"2011","unstructured":"Shah DK, Balthasar JP. Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn. 2011;38(1):121\u201342.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1641_CR89","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s10875-018-0560-5","volume":"38","author":"S Jolles","year":"2018","unstructured":"Jolles S, Rojavin MA, Lawo JP, Nelson R Jr., Wasserman RL, Borte M, et al. Long-term efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency in Japan, Europe, and the United States: a review of 7 phase 3 trials. J Clin Immunol. 2018;38(8):864\u201375.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1641_CR90","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s10875-020-00788-5","volume":"40","author":"JL Lee","year":"2020","unstructured":"Lee JL, Mohamed Shah N, Makmor-Bakry M, Islahudin FH, Alias H, Noh LM, et al. A systematic review and meta-regression analysis on the impact of increasing IgG trough level on infection rates in primary immunodeficiency patients on intravenous IgG therapy. J Clin Immunol. 2020;40(5):682\u201398.","journal-title":"J Clin Immunol"},{"key":"1641_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116497","volume":"408","author":"JA Allen","year":"2020","unstructured":"Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? J Neurol Sci. 2020;408:116497.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1641_CR92","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94\u2013100.","journal-title":"J Clin Immunol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01641-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01641-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01641-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:08:42Z","timestamp":1781651322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01641-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01641-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SZ, MC, and TP have no competing interests to declare. ST received funding for research from Octapharma (all paid to institution). VASHD received funding for research from Takeda, CSL Behring, Pharming and Moderna (all paid to institution), and honoraria for lectures from AstraZeneca, Pfizer, Pharming, Takeda, CSL Behring and Johnson & Johnsons (all paid to institution). BCJ received funding for research from Sanquin, Grifols, Octapharma and CSL-Behring (all paid to institution). BK is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation:\n                      Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers;\n                      Methodology:\n                      Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers;\n                      Formal analysis and investigation:\n                      Shannon van der Zeeuw, Sander van Tilburg;\n                      Writing \u2013 original draft preparation:\n                      Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers;\n                      Writing \u2013 review and editing:\n                      Shannon van der Zeeuw, Sander van Tilburg, Rose Crombag, Birgit Koch, Virgil Dalm, Tim Preijers, Bart Jacobs;\n                      Funding acquisition:\n                      none;\n                      Resources:\n                      Shannon van der Zeeuw, Sander van Tilburg;\n                      Supervision:\n                      Rose Crombag, Birgit Koch, Virgil Dalm, Tim Preijers, Bart Jacobs.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}